Disc Medicine director granted 6,212 stock options

Disc Medicine, Inc. director Georges Gemayel received a grant of stock options covering 6,212 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Disc Medicine, Inc. director Georges Gemayel received a grant of stock options covering 6,212 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036, bringing his reported derivative holdings to 6,212 options.

The options vest on the earlier of the company’s 2027 annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues to serve as a director on the vesting date.

Insider Trade Summary

Grant/Award: 6,212 shares

Grant/Award 1 txn

Insider GEMAYEL GEORGES

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,212	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,212 contracts (Direct)

Footnotes (1)

F1. The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 6,212 options Exercise price: $70.79 per share Underlying shares: 6,212 shares +2 more

5 metrics

Options granted 6,212 options Stock Option (Right to Buy) grant on June 18, 2026

Exercise price $70.79 per share Conversion or exercise price for granted options

Underlying shares 6,212 shares Common stock underlying the option grant

Expiration date June 17, 2036 Options expire on this date

Post-grant derivative holdings 6,212 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), grant/award acquisition, conversion or exercise price, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

conversion or exercise price financial

"conversion_or_exercise_price: 70.7900"

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"The shares underlying this option vest upon the first to occur"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Disc Medicine (IRON) director Georges Gemayel report on this Form 4?

Georges Gemayel reported receiving a grant of stock options for 6,212 shares of Disc Medicine common stock. These options are a compensation award, not an open-market stock purchase or sale, and are reported as a derivative acquisition on Form 4.

What are the key terms of Georges Gemayel’s new Disc Medicine (IRON) stock options?

The grant covers 6,212 options with an exercise price of $70.79 per share and an expiration date of June 17, 2036. Each option represents the right to buy one share of Disc Medicine common stock under these terms.

When do the new Disc Medicine (IRON) options granted to Georges Gemayel vest?

The options vest on the first to occur of the company’s 2027 annual stockholder meeting or the one-year anniversary of the grant date. Vesting requires Gemayel’s continued service as a director through the chosen vesting date.

Is Georges Gemayel buying or selling Disc Medicine (IRON) shares in this filing?

This filing reports an acquisition of stock options as a grant, not a market trade. No open-market buy or sell transactions are disclosed; instead, the company awarded options as part of director compensation.

How many Disc Medicine (IRON) derivative securities does Georges Gemayel hold after this grant?

After this transaction, Gemayel holds 6,212 stock options directly, according to the filing’s post-transaction total. Each option is exercisable for one share of Disc Medicine common stock at the stated exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 04:59 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEMAYEL GEORGES

(Last)

(First)

(Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$70.79	06/18/2026		A		6,212		⁽¹⁾	06/17/2036	Common Stock	6,212	$0	6,212	D

Explanation of Responses:

1. The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

	/s/ Rahul Khara, attorney-in-fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR